tiprankstipranks
Genmab A/S (GB:0MGB)
LSE:0MGB
UK Market
0MGB
Genmab A/S
RESEARCH TOOLSreports

Genmab A/S (0MGB) Stock News & Sentiment

14 Followers
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
Premium
Ratings
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
6h ago
GMAB
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
Premium
Ratings
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
2M ago
GMAB
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
Premium
Ratings
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
2M ago
GMAB
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
Premium
Ratings
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
2M ago
GMAB
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
Premium
Ratings
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
2M ago
GMAB
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
Premium
Ratings
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
2M ago
GMAB
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
Premium
Ratings
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
2M ago
GMAB
More GB:0MGB News >

0MGB News on the Web

Genmab reports Darzalex Q1 worldwide sales $3.964B
TipRanks News
Bullish
Balancing Strong Near‑Term Execution With Long‑Term Patent and Pipeline Uncertainty at Genmab
TipRanks News
Neutral
Genmab presents safety, tolerability data on Rina-S with bevacizumab
TipRanks News
Bullish
Wells Fargo Sticks to Its Buy Rating for Genmab (GMAB)
TipRanks News
Bullish
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
TipRanks News
Neutral
UBS Remains a Buy on Genmab A/S (0MGB)
TipRanks News
Bullish
Genmab initiated with an Outperform at Wolfe Research
TipRanks News
Bullish
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
GB:0MGB
Sector Average
Media Buzz
This Week3 articles
Weekly Average1.75 articles
News Sentiment
This Week100%
Sector Average60%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GB:0MGB’s Media Buzz Sentiment?
3 articles about GB:0MGB were published this week. In an average week, 1.75 articles are published.
    What is GB:0MGB’s weekly average amount of articles?
    In an average week, 1.75 articles about GB:0MGB are published.
      What is GB:0MGB’s News Sentiment?
      100% of articles about GB:0MGB were positive this week, compared to its sector average of 60%.
        General Stocks that are Trending in the News
        JANJanus Living, Inc. Class A
        SZYCFSaizeriya Co
        THXThor Explorations
        0J3FSodexo SA
        LUCALuca Mining
        Showing the stocks with the most bullish news sentiment over the past week